Patients with CML showing higher BCR::ABL1 levels at diagnosis would be exposed to a higher risk of developing disease progression caused by a higher proliferation rate, thereby inducing additional molecular alterations that increase the persistence of peripheral blast cells. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.